tbuckley/cabot-search huggingface dataset:
FRI0600 Fears and Beliefs of People Living with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis: A Systematic Literature Review
Authors: P.E. Palominos, L. Gossec, N. Andrade, A. Gasparin, F. Igansi, R. Chakr, R. Xavier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Despite the growing interest of rheumatologists into the patients9 perspective in the last decade (1) and the wide use of patient-reported outcomes in the assessment of Rheumatoid Arthritis (RA) (2,3) and Spondyloarthritis (SpA) (4), the main fears and beliefs of these group of patients and their consequences on treatment outcomes are unclear. <h3>Objectives</h3> To assess the main fears and beliefs of people with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from different continents and their effect on treatment outcomes; <h3>Methods</h3> A systematic literature review was conducted in Pubmed/Medline. All original articles published up to December 2014, reporting fears and/or beliefs of adult patients with RA, AS or PsA were analyzed. Fears and beliefs were collected by two independent researchers and grouped in categories. <h3>Results</h3> Of the 293 publications identified, 70 were analyzed, corresponding to 19,161 RA, 1,693 AS/Spondyloarthritis and 202 PsA patients. No article reported fears and/or beliefs of people living in Latin America, Africa or Oceania. Fears were reported in 19 articles of which 9 (47.4%) reported fears related to pharmacological therapy. Beliefs were reported in 59 articles: beliefs about the rheumatic disorder were found to affect the impact of disease (in N=24 articles, 40.7% of articles assessing beliefs), beliefs about therapy were sometimes linked to adherence (N=11, 18.6%) and beliefs about cause of disease influenced coping strategies and adherence (N=5, 8.5%). Beliefs mediated the emotional impact of disease in RA (N=9, 15.2%) and influenced functioning in AS and RA (N=4, 6.8%). <h3>Conclusions</h3> Patients9 beliefs are linked to impact of disease and non-adherence in RA, AS and PsA. Further research is needed on fears of PsA and AS patients and on fears/ beliefs of patients living outside Europe and North America. <h3>References</h3> Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. Tillett W, Eder L, Goel N, De Wit M, Gladman DD, FitzGerald O et al. J Rheumatol. 2015; 42(11): 2198–203. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. Gossec L, Dougados M, Dixon W. RMD Open. 2015; 2:1(1). Reporting of patient-reported outcomes in recent trials of rheumatoid arthritis:a systematic literature review. Kalyoncu U, Dougados M, Daurès JP, Gossec L. Ann Rheum Dis.2009;68 (2): 183–90. Clinical outcomes in psoriatic arthritis: A systematic literature review. Palominos PE, Gaujaux-Viala C, Fautrel B, Dougados M, Gossec L. Arthritis Care Res (Hoboken). 2012; 64(3): 397–406. <h3>Disclosure of Interest</h3> None declared
Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model
Authors: Elodie Lesteven, Doriane Pognant, Valerie Vanneaux, Jérome Larghero, Olivier Feraud, Annelise Bennaceur-Griscelli, Emmanuelle Verger, Annalisa Andreoli, Christine Chomienne, Bruno Cassinat, Jean-Jacques Kiladjian
Journal: Blood (2014)
THU0008 Leucine-Rich Alpha 2 Glycoprotein Promotes The Differentiation of Th17 and Deteriorates Collagen Induced Arthritis through Enhancement of TGF Beta Signaling
Authors: H. Urushima, M. Fujimoto, T. Mishima, T. Ohkawara, H. Honda, S. Serada, T. Naka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> We have identified leucine-rich alpha 2 glycoprotein (LRG) as a disease marker of rheumatoid arthritis (RA) <sup>1)</sup>. Although LRG is produced in site of inflammation such as synovial tissues, its function is still unclear. Recently, LRG is reported to bind with TGF-β and enhance of Smad2 phosphorylation <sup>2)</sup>. TGF-β is essential for differentiation of Th17. Th17 plays important roles in the pathogenesis of RA, for example, by regulating osteoclast differentiation. In collagen induced arthritis (CIA), a mouse model of RA, phosphorylation of Smad2 in CD4 T cells is important for the Th17 differentiation and the induction of arthritis <sup>3)</sup>. Thus, LRG may be involved in the pathogenesis of RA through the regulation of T lymphocyte differentiation. <h3>Objectives</h3> In this study, we aimed to elucidate the function of LRG on T lymphocyte differentiation and to examine the involvement of LRG in the pathogenesis of RA. <h3>Methods</h3> Naïve T lymphocyte were isolated from WT or LRG KO mice to examine the effects of LRG on the differentiation into Th17 and Treg in the absence or presence of recombinant LRG. Male C57BL/6 mice and LRG KO mice were subjected to collagen-induced arthritis (CIA). <h3>Results</h3> In the presence of TGF-β alone, the differentiation of Treg was promoted by LRG. However, in the presence both TGF-β and IL6, LRG enhanced the differentiation into Th17 by increasing both Smad2 and STAT3 phosphorylation. The phosphorylation of p38 was also increased by LRG. In addition, the expression of IL6 receptor in naïve T cells was significantly lower in LRG KO mice than in WT mice. In CIA model, arthritis score was significantly lower in LRG KO mice than in control group. The numbers of Th17 in regional lymph nodes and serum levels of IL17 were significantly lower in LRG KO mice than in WT mice. <h3>Conclusions</h3> LRG promoted TGF-β-induced Smad2 phosphorylation under Th17 differentiation condition. Since Smad2 signal increases the expression of IL6 receptor in naïve T cells <sup>4)</sup>, LRG might increase the expression of IL6 receptor through Smad2 signal, leading to enhanced the phosphorylation of STAT3 which is an essential transcription factor in the differentiation of Th17 <sup>4)5)</sup>. LRG also enhanced phosphorylation of p38 MAPK which is involved in the proliferation of helper T cells. In addition, recent study reported that p38 MAPK plays an important role in the production of IL17 <sup>6)7)</sup> Taken together, our study suggested that LRG promotes both the proliferation and Th17 differentiation of naive T cells under inflammatory state, leading to deterioration of arthritis. <h3>References</h3> Ann Rheum Dis 2010 Oncotarget 2015 Nat Commun 2015 J Biol Chem 2010 Nat Commun 2015 J Immunol 2010 Blood 2011 <h3>Disclosure of Interest</h3> None declared
Refractory Autoimmune Cytopenias, Either Associated with Lymphoproliferative Diseases or Idiopathic in Adult Patients, Treated with Anti-CD20 Monoclonal Antibody (Rituximab).
Authors: Guy Garay, Dardo Riveros, Jorge Milone, Jose Fernandez, Patricio Duarte, Roberto Cacchione, Juan Dupont
Journal: Blood (2004)
Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.
Authors: Jürgen Krauter, Katharina Wagner, Irina Schäfer, Rolf Marschalek, Claus Meyer, Gerhard Heil, Markus Andreas Schaich, Gerhard Ehninger, Dietger W. Niederwieser, Rainer Krahl, Konstanze Dohner, Hartmut Dohner, Richard Schlenk, Arnold Ganser
Journal: Blood (2006)
E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma
Authors: Matthew E. Spector, Assuntina G. Sacco, Emily Bellile, Jeremy M.G. Taylor, Tamara Jones, Kan Sun, William C. Brown, Andrew C. Birkeland, Carol R. Bradford, Gregory T. Wolf, Mark E. Prince, Jeffrey S. Moyer, Kelly Malloy, Paul Swiecicki, Avraham Eisbruch, Jonathan B. McHugh, Douglas B. Chepeha, Laura Rozek, Francis P. Worden
Journal: Clinical Cancer Research (2016)

Purpose: There is a paucity of biomarkers to predict failure in human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) following curative therapy. E6/E7 viral oncoproteins are constitutively expressed in HPV+ tumors and highly immunogenic, resulting in readily detected serum antibodies. The purpose of this study is to determine whether serum E6 and E7 antibody levels can potentially serve as a biomarker of recurrence in patients with HPV+OPSCC.Experimental Design: We evaluated E6/E7 antibody levels in patients with previously untreated, advanced stage (III, IVa-b), HPV+OPSCC receiving definitive chemoradiation under a uniform protocol from 2003 to 2010. Baseline and longitudinal serum samples were obtained from our archived repository. E6/E7 serum levels were measured using a glutathione-S-transferase capture ELISA and quantified by approximating the area under the dilution curve, and were analyzed using ANOVA and linear mixed model for longitudinal analysis.Results: We compared 22 HPV+OPSCC patients who developed recurrence with 30 patients who remained disease-free. There were no differences in T classification, N classification, disease subsite, or smoking status between the groups. In a longitudinal analysis, recurrent patients had significantly higher E6 and E7 serum antibody levels than the nonrecurrent patients over the follow-up period (P = 0.02 and P = 0.002, respectively). Patients who recurred had a lower clearance of E7 antibody than patients who remained disease-free (P = 0.0016).Conclusions: Patients with HPV+OPSCC whose disease recurs have a lower clearance of E6 and E7 antibodies than patients who do not have recurrence. The ratio of E7 antibody at disease recurrence compared with baseline is potentially a clinically significant measurement of disease status in HPV+OPSCC. Clin Cancer Res; 23(11); 2723-9. ©2016 AACR.
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant
Authors: Neil Mehta, Julie Heimbach, Denise M. Harnois, Gonzalo Sapisochin, Jennifer L. Dodge, David Lee, Justin M. Burns, William Sanchez, Paul D. Greig, David R. Grant, John P. Roberts, Francis Y. Yao
Journal: JAMA Oncology (2016)

Several factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reliable risk score has been established to determine the individual risk for HCC recurrence.We aimed to develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for patients with HCC meeting Milan criteria by imaging.Predictors of recurrence were tested in a development cohort of 721 patients who underwent LT between 2002 and 2012 at 3 academic transplant centers (University of California-San Francisco; Mayo Clinic, Rochester; and Mayo Clinic, Jacksonville) to create the RETREAT score. This was subsequently validated in a cohort of 341 patients also meeting Milan criteria by imaging who underwent LT at the University of Toronto transplant center using the C concordance statistic and net reclassification index.Characteristics associated with post-LT HCC recurrence.A total of 1061 patients participated in the study; 77.8% (825) were men, and the median (IQR) age was 58.2 (53.3-63.9) years in the development cohort and 56.4 (51.7-61.0) years in the validation cohort (P < .001). In the development cohort of 721 patients (542 men), median α-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL; 9.4% had microvascular invasion (n = 68), and 22.1% were beyond Milan criteria on explant (n = 159) owing to understaging by pretransplantation imaging. Cumulative probabilities of HCC recurrence at 1 and 5 years were 5.7% and 12.8%, respectively. On multivariable Cox proportional hazards regression, 3 variables were independently associated with HCC recurrence: microvascular invasion, AFP at time of LT, and the sum of the largest viable tumor diameter and number of viable tumors on explant. The RETREAT score was created using these 3 variables, with scores ranging from 0 to 5 or higher that were highly predictive of HCC recurrence (C statistic, 0.77). RETREAT was able to stratify 5-year post-LT recurrence risk ranging from less than 3% with a score of 0 to greater than 75% with a score of 5 or higher. The validation cohort (n = 340; 283 men) had significantly higher microvascular invasion (23.8% [n = 81], P < .001), explant beyond Milan criteria (37.3% [n = 159], P < .001), and HCC recurrence at 5 years (17.9% [n = 159], P = .03). RETREAT showed good model discrimination (C statistic, 0.82; 95% CI, 0.77-0.86) and superior recurrence risk classification compared with explant Milan criteria (net reclassification index, 0.40; P = .001) in the validation cohort.We have developed and validated a simple and novel prognostic score that may improve post-LT HCC surveillance strategies and help identify patients who may benefit from future adjuvant therapies.
Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation,
Authors: Jungwon Huh, Heeje Kim, Woo-Sung Min, Chul Won Jung, Hee-Jin Kim, Sun-Hee Kim, Yeo-Kyeoung Kim, Hyeoung Joon Kim, Joon Ho Moon, Sang Kyun Sohn, Sung Hyun Kim, Won Sik Lee, Jong-Ho Won, Yeung-Chul Mun, Hawk Kim, Jeeny Park, Dennis Dong Hwan Kim
Journal: Blood (2011)
AB0809 Efficacy and Safety of A Personalized Nutritional Diet in Gouty Patients in Cameroon: A Pilot Study: Table 1.
Authors: F. Kemta Lekpa, H.D.G. Mbiatat, M.S. Doualla, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Many guidelines from different parts of the world mention the impact of diet on gout (1). However, data are scarce in sub-Saharan Africa. <h3>Objectives</h3> To evaluate the efficacy and safety of a gouty apurinic personalized diet based on ethnic origin, dietary habits and patient comorbidities. <h3>Methods</h3> Gout (177 ACR preliminary criteria) patients with serum urate levels &gt;70g/dL were recruited. Patients were randomized to receive a standard diet apurinic gout or a personalized diet. At 1 month, all patients in the standard diet group were put under the personalized diet. The primary endpoint was the reduction of serum uric acid at 1 month (M1) and 3 months (M3). Secondary outcomes were the number of gout attacks and changes in anthropometric measures at M1 and M3. A <i>p</i>&lt;0.05 was considered statistically significant. <h3>Results</h3> Of the 30 patients randomized, 12 patients have not respected their diet. Only 18 were retained in the final analysis: 10 patients on personalized diet group and 8 on standard diet group. The baseline characteristics of both groups were similar at baseline (p&gt;0.05). At M1, we have observed a significant decrease in serum uric acid in the personalized diet group compared to the standard diet group (p=0.0001). We have observed 5 acute gout attacks in the standard diet group against 2 acute gout attacks in the personalized diet group (p=0.03). A trend of decrease was observed for all other parameters without significance (p&gt;0.05) [Table 1]. At M3, all patients received personalized diet. Initial efficacy was maintained in all the patients of the personalized diet group. For patients of the standard diet group, we observed a significant decrease in serum uric acid (p=0.02). There was no difference in the number of acute gout attacks (p=0.08). A trend of decrease was also observed for all other parameters without significance (Table 1). No adverse events related to both diet group were observed. <h3>Conclusions</h3> This study shows that the diet should be personalized in gouty patients according to socio-cultural environment, lifestyle, and comorbidities of each patients. Efforts should be made to improve compliance to diet like other non-pharmacological and pharmacological treatment. <h3>References</h3> Khanna D et al. Arthritis Care Res (Hoboken) 2012;64:1447–61. <h3>Disclosure of Interest</h3> None declared
EZH2 Mutations Are Associated with Low Blast Percentage in Bone Marrow and −7/Del(7q) Karyotype in De Novo Acute Myeloid Leukemia.
Authors: Xiuli Wang, Haiping Dai, Qian WANG, Qinrong Wang, Yang Xu, Zhengming Jin, Jianying Liang, Huiying Qiu, Aining Sun, Changgeng Ruan, Jia Ruan, Suning Chen, Wu Depei
Journal: Blood (2012)
Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
Authors: Zoe Hall, Nicholas J. Bond, Tom Ashmore, Francis Sanders, Zsuzsanna Ament, Xinzhu Wang, Andrew J. Murray, Elena Bellafante, Sam Virtue, Antonio Vidal‐Puig, Michael Allison, Susan E. Davies, Albert Koulman, Michele Vacca, Julian L. Griffin
Journal: Hepatology (2016)

Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion : NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (H epatology 2017;65:1165‐1180)
Patient care is at risk from lack of new funds in autumn statement, healthcare leaders warn
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The government’s failure to commit new funding to the NHS and social care in its autumn statement will put the care of patients at risk, health and social care leaders have warned.

The government was strongly urged ahead of the 23 November statement to revisit its 2015 spending review pledges for health and social care because of the severe pressures across the service.

But the chancellor of the exchequer, Philip Hammond, ignored the calls and repeated the increasingly discredited claim that the government had already committed £10bn (€11.7bn; $12.4bn) extra funding for the NHS by 2020.1

The autumn statement said that the government would honour all …
PWE-128 The Out-of-Hours Gastrointestinal Bleed Service in South-West London: A Model for Regional Emergency Endoscopy Cover: Abstract PWE-128 Table 1
Authors: C Alexakis, V Chhaya, I Sutherland, R Lalani, O Tavabie, R Hewett, D Chan, G Amarasinghe, J Ryan, S Uppal, N Inayet, C Woodhouse, B Kok, G Chakrabarty, S Moodie, P Patel, S Zar, A Mahmood, G Sadler, C Groves, S Gupta, S Clark
Journal: Gut (2016)

<h3>Introduction</h3> Gastrointestinal (GI) bleeding is associated with a mortality of 10–30%. An NCEPOD report recently recommended that management of GI bleeds should be directed by a named GI bleed clinician, although wasn’t implicit that procedures be performed by a consultant.<sup>1</sup> In SW London, 5 hospitals developed a network service to cover out-of-hours emergency endoscopy requirements for the region. It is a registrar-delivered, consultant-supported service. We present the key service outputs over a 10 month period in 2015. <h3>Methods</h3> OGDs were performed by registrars accredited with appropriate skills in upper endoscopy. Endoscopists prospectively collected data on all out-of-hours OGDs performed including age and sex of patient, Rockall score, time to OGD, primary endoscopic findings and therapeutic intervention. Data on mortality and re-bleed rates were retrospectively collected for the last 2 months of the study. <h3>Results</h3> 172 out-of-hours OGDs were performed between March and December 2015. 57% occured during the weekend, giving rise to a procedure rate of 1.12 OGD/weekend day and 0.33 OGD/week day. Mean age of patient was 59.5 years (range 16–94). 64% were male. Median Rockall score was 4. Mean time to OGD was 4hrs 15 mins (range 1 hr-16hrs). Table 1 shows the primary pathologies at OGD. Therapeutic intervention was needed in 52% of cases. Failure to achieve haemostasis endoscopically occured in 1.7%. Consultant assistance was required in 3 cases. Data from Nov to Dec 2015, which included 40 OGDs (mean age 59 years, 63% males, intervention rate 53%) indicated an inpatient re-bleed rate of 10% (NCEPOD audit rate 23%), an interventional radiology requirement in 6% (NCEPOD 8%) and a surgical intervention rate of 2.5% (NCEPOD 6%). All-cause 30 day mortality rate was 15%, although only one patient (2.5%) died as a direct result of uncontrolled bleeding. <h3>Conclusion</h3> The results indicate that an effective and safe regional out-of-hours emergency GI bleed service can be provided via a registrar-delivered, consultant-supported model. This has important implications when considering the development of consultant on-call rosters, and maximising training opportunities for registrars. <h3>Reference</h3> 1 NCEPOD ‘Time to get control’ – a review of the care received by patients who had a severe gastrointestinal haemorrhage 2015. <h3>Disclosure of Interest</h3> None Declared
Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).
Authors: Thomas S. Lin, Beth Fischer, Kristie A. Blum, Leslie A. Andritsos, Jeffrey A. Jones, Mollie E. Moran, Sarah Broering, Nyla A. Heerema, Gerard Lozanski, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, Lisa L. Smith, Amy J. Wagner, Chelsey A. Raymond, Mitch Phelps, James T. Dalton, Michael R. Grever, John C. Byrd
Journal: Blood (2007)
Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen‐induced rhinoconjunctivitis – an <scp>EAACI</scp> position paper
Authors: O. Pfaar, K. Bastl, U. Berger, J. Buters, M. A. Calderon, B. Clot, U. Darsow, P. Demoly, S. R. Durham, C. Galán, R. Gehrig, R. Gerth van Wijk, L. Jacobsen, L. Klimek, M. Sofiev, M. Thibaudon, K. C. Bergmann
Journal: Allergy (2016)

Clinical efficacy of pollen allergen immunotherapy (AIT) has been broadly documented in randomized controlled trials. The underlying clinical endpoints are analysed in seasonal time periods predefined based on the background pollen concentration. However, any validated or generally accepted definition from academia or regulatory authorities for this relevant pollen exposure intensity or period of time (season) is currently not available. Therefore, this Task Force initiative of the European Academy of Allergy and Clinical Immunology (EAACI) aimed to propose definitions based on expert consensus.A Task Force of the Immunotherapy and Aerobiology and Pollution Interest Groups of the EAACI reviewed the literature on pollen exposure in the context of defining relevant time intervals for evaluation of efficacy in AIT trials. Underlying principles in measuring pollen exposure and associated methodological problems and limitations were considered to achieve a consensus.The Task Force achieved a comprehensive position in defining pollen exposure times for different pollen types. Definitions are presented for 'pollen season', 'high pollen season' (or 'peak pollen period') and 'high pollen days'.This EAACI position paper provides definitions of pollen exposures for different pollen types for use in AIT trials. Their validity as standards remains to be tested in future studies.